Kyoung Sik Park

Prof. Dr. Kyoung Sik Park

Department of Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Subbroto SahaSubbroto Saha
Subbroto Saha
S. IslamS. Islam
S. Islam
MAM. Abdullah-Al-Wadud
M. Abdullah-Al-Wadud
Saiful IslamSaiful Islam
Saiful Islam
FAFarman Ali
Farman Ali
Kyoung Sik ParkKyoung Sik Park
Kyoung Sik Park
Kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) are dysregulated in many cancers, making them appealing targets for cancer therapy. However, their use as prognostic biomarkers is controversial and remains an active area of cancer research. Here, we performed a systematic multiomic analysis to determine whether glutaminases function as prognostic biomarkers in human cancers. Glutaminase expression and methylation status were assessed and their prominent functional protein partners and correlated genes were identified using various web-based bioinformatics tools. The cross-cancer relationship of glutaminases with mutations and copy number alterations was also investigated. Gene ontology (GO) and pathway analysis were performed to assess the integrated effect of glutaminases and their correlated genes on various cancers. Subsequently, the prognostic roles of GLS and GLS2 in human cancers were mined using univariate and multivariate survival analyses. GLS was frequently over-expressed in breast, esophagus, head-and-neck, and blood cancers, and was associated with a poor prognosis, whereas GLS2 overexpression implied poor overall survival in colon, blood, ovarian, and thymoma cancers. Both GLS and GLS2 play oncogenic and anti-oncogenic roles depending on the type of cancer. The varying prognostic characteristics of glutaminases suggest that GLS and GLS2 expression differentially modulate the clinical outcomes of cancers.

Verified
Journal Article
Open access
PDF file
TJTongYi Jin
TongYi Jin
Kyoung Sik ParkKyoung Sik Park
Kyoung Sik Park
SNSang Eun Nam
Sang Eun Nam
YYYoung Bum Yoo
Young Bum Yoo
WPWon Seo Park
Won Seo Park
IYIk Jin Yun
Ik Jin Yun
BRCA1/2 are breast cancer susceptibility genes that are involved in DNA repair and transcriptional control. They are dysregulated in breast cancer, making them attractive therapeutic targets. Here, we performed a systematic multiomics analysis to expound BRCA1/2 functions as prognostic biomarkers in breast cancer. First, using different web-based bioinformatics platforms (Oncomine, TIMER 2.0, UALCAN, and cBioportal), the expression of BRCA1/2 was assessed. Then, the R package was used to analyze the diagnostic value of BRCA1/2 in patients. Next, we determined the relationship between BRCA1/2 mRNA expression and prognosis in patients (PrognoScan Database, R2: Kaplan Meier Scanner and Kaplan–Meier Plotter). Subsequently, the association of BRCA1/2 with mutation frequency alteration and copy number alterations in breast cancer was investigated using the cBioportal platform. After that, we identified known and predicted structural genes and proteins essential for BRCA1/2 functions using GeneMania and STRING db. Finally, GO and KEGG pathway enrichment analyses were performed to elucidate the potential biological functions of the co-expression genes of BRCA1/2. The BRCA1/2 mRNA level in breast cancer tissues was considerably higher than in normal tissues, with AUCs of 0.766 and 0.829, respectively. Overexpression of BRCA1/2 was significantly related to the worse overall survival (p < 0.001) and was correlated to clinicopathological characteristics including lymph nodes, estrogen receptors, and progesterone receptors (p < 0.01). The alteration frequencies of both the gens have been checked, and the results show that BRCA1 and BRCA2 show different alteration frequencies. Their mutation sites differ from each other. GO and KEGG showed that BRCA1/2 was mainly enriched in catalytic activity, acting on DNA, chromosomal region, organelle fission, cell cycle, etc. The 20 most frequently changed genes were closely related to BRCA1/2, including PALB2 and RAD51 relatively. Our study provides suggestive evidence of the prognostic role of BRCA1/2 in breast cancer and the therapeutic target for breast cancer. Furthermore, BRCA1/2 may influence BRCA prognosis through catalytic activity, acting on DNA, chromosomal regions, organelle fission, and the cell cycle. Nevertheless, further validation is warranted.

Verified
Journal Article
Open access
PDF file
PBPolash Kumar Biswas
Polash Kumar Biswas
YKYEONJOO KWAK
YEONJOO KWAK
AKAram Kim
Aram Kim
JSJaekwon Seok
Jaekwon Seok
HKHee Jeong Kwak
Hee Jeong Kwak
Ssang-Goo ChoSsang-Goo Cho
Ssang-Goo Cho
Tweety family member 3 (TTYH3) is a calcium-activated chloride channel with a non-pore-forming structure that controls cell volume and signal transduction. We investigated the role of TTYH3 as a cancer-promoting factor in bladder cancer. The mRNA expression of TTYH3 in bladder cancer patients was investigated using various bioinformatics databases. The results demonstrated that the increasingly greater expression of TTYH3 increasingly worsened the prognosis of patients with bladder cancer. TTYH3 knockdown bladder cancer cell lines were constructed by their various cancer properties measured. TTYH3 knockdown significantly reduced cell proliferation and sphere formation. Cell migration and invasion were also significantly reduced in knockdown bladder cancer cells, compared to normal bladder cancer cells. The knockdown of TTYH3 led to the downregulation of H-Ras/A-Raf/MEK/ERK signaling by inhibiting fibroblast growth factor receptor 1 (FGFR1) phosphorylation. This signaling pathway also attenuated the expression of c-Jun and c-Fos. The findings implicate TTYH3 as a potential factor regulating the properties of bladder cancer and as a therapeutic target.

1 January 2015 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
SPSang O Park
Sang O Park
YYYoung Bum Yoo
Young Bum Yoo
YKYong Hun Kim
Yong Hun Kim
KBKwang Je Baek
Kwang Je Baek
JYJung-Hyun Yang
Jung-Hyun Yang
Kyoung Sik ParkKyoung Sik Park
Kyoung Sik Park
Park SO, et al. Ann Surg Treat Res. 2015 Feb;88(2):55-62. http://dx.doi.org/10.4174/astr.2015.88.2.55

1 January 2020 in Cancer Informatics
Verified
Journal Article
Open access
PDF file
MSMadhuri Saindane
Madhuri Saindane
HRHarikrishna Reddy Rallabandi
Harikrishna Reddy Rallabandi
Kyoung Sik ParkKyoung Sik Park
Kyoung Sik Park
AHAlexander Heil
Alexander Heil
SNSang Eun Nam
Sang Eun Nam
IYIk Jin Yun
Ik Jin Yun
Prostaglandin-endoperoxide synthase-2 (PTGS2) plays a pivotal role in inflammation and carcinogenesis in human breast cancer. Our aim of the study is to find the prognostic value of PTGS2 in breast cancer. We conducted a multiomic analysis to determine whether PTGS2 functions as a prognostic biomarker in human breast cancer. We explored PTGS2 mRNA expressions using different public bioinformatics portals. Oncomine, Serial Analysis of Gene Expression (SAGE), GEPIA, ULCAN, PrognoScan database, Kaplan-Meier Plotter, bc-GenExMiner, USC XENA, and Cytoscape/STRING DB were used to identify the prognostic roles of PTGS2 in breast cancer. Based on the clinicopathological analysis, decreased PTGS2 expressions correlated positively with older age, lymph node status, the human epidermal growth factor receptor 2 (HER2) status (P < .0001), estrogen receptor (ER+) expression (P < .0001) Luminal A (P < .0001), and Luminal B (P < .0001). Interestingly, progesterone receptor (PR) (P < .0001) negative showed a high expression of PTGS2. Prostaglandin-endoperoxide synthase-2 was downregulated in breast cancer tissues than in normal tissues. In the PrognoScan database and, Kaplan-Meier Scanner, downregulated expressions of PTGS2 associated with poor overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival. The methylation levels were significantly higher in the Luminal B subtype. Through oncomine coexpressed gene analysis, we found a positive correlation between PTGS2 and interleukin-6 (IL-6) expression in breast cancer tissues. These results indicate that downregulated expressions of PTGS2 can be used as a promising prognostic biomarker and Luminal B hyper methylation may play an important role in the development of breast cancers. However, to clarify our results, extensive study is required.

1 January 2015 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
MCMin Ji Cho
Min Ji Cho
Kyoung Sik ParkKyoung Sik Park
Kyoung Sik Park
MCMin Jeng Cho
Min Jeng Cho
YYYoung Bum Yoo
Young Bum Yoo
JYJung Hyun Yang
Jung Hyun Yang
Cho MJ, et al. Ann Surg Treat Res. 2015 Feb;88(2):69-76. http://dx.doi.org/10.4174/astr.2015.88.2.69